HomeAI · summaries
Storia in 3 fonti
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
- ·
fiercepharma.com
ASCO: Pfizer one-ups J&J with Talzenna combo's broad castration-sensitive prostate cancer win
Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer. | After winning a broader FDA label in metastatic castration-resistant…
- ·
medpagetoday.com
Treatment Intensification Slows Metastatic Hormone-Sensitive Prostate Cancer
Talazoparib plus enzalutamide reduces progression risk by 50% in men with DNA repair alterations